


Suppl Figure 6



*S*Figure 6. Bevacizumab treatment causes a reduction in phospho-VEGFR2 and downregulation of VEGF-A induces autophagy in CD133<sup>+</sup> GBM cells. **A&B**, CD133<sup>+</sup> GBM cells were plated and treated with bevacizumab as described in Figure 3A&B for 48 hr. Cells were then reacted with mouse mAb anti-VEGFR2 and rabbit anti-phosphotyrosine antibodies, followed by Alexa-488- and Alexa-594-secondary

antibodies, DAPI nuclear stain, coverslipping and microscopy (A). Quantitation of colocalization from 10 fields/condition was performed using ImageJ, and the colocalization plotted as the mean $\pm$ SEM (B). Statistical analysis: two-sided exact Wilcoxon rank-sum test ( $p$  value  $<0.05$ ). **C**, Downregulation of VEGF-A with siRNA induces colocalization of LC3-LAMP2 puncta. CD133<sup>+</sup> cells were treated with siVEGF-A or control siRNA for 48 h. Cells were then reacted with anti-LC3 antibody (2  $\mu$ g/ml) and anti-LAMP2 antibody (4  $\mu$ g/ml), followed by Alexa-488- and Alexa-594-secondary antibodies, DAPI nuclear stain, coverslipping and confocal microscopy. Quantitation of the number of LC3-LAMP2 puncta/cell (ImageJ) is graphed as the mean $\pm$ SEM. Statistical analysis: Wilcoxon rank-sum test ( $p=0.04$ ).